The impact of genomics on global healthcare is one to watch. Genomic testing is improving the diagnosis and treatment of diseases including cancer, genetic and infectious diseases; driving the delivery of more personalised care.

As global research and the understanding of genomics grows, the view on familial brain aneurysm syndrome continues to develop. Determining whether there is a genetic foundation to this rare disease can bring answers to the families affected by, and at risk of, this condition.

Surgical robotics technology adoption is expected to accelerate with China’s push towards digitalisation of healthcare. Already, a three-year action plan set in motion in 2018 to promote the “new generation artificial intelligence industry” has highlighted the country’s need for surgical robots.

The impact of genomics on global healthcare is one to watch. Genomic testing is improving the diagnosis and treatment of diseases. Next-generation sequencing technologies enable noninvasive prenatal testing (NIPT) to screen for diseases early, including thalassemia.

Lung cancer is the leading cause of cancer mortality in the Asia-Pacific (APAC) region, with annual deaths expected to increase to over 1.8m by 2040. In vitro diagnostics (IVD) technologies such as immunoassays, tissue diagnostics, next-generation sequencing and PCR liquid biopsy are used to test for lung cancer biomarkers.

An IVD multinational company is preparing to roll out a new value proposition for its portfolio of core lab solutions globally. For its new value proposition to resonate successfully with potential customers, the client needed to first test its reception with potential customers in core labs.

Digital health technologies will continue to transform surgical procedures worldwide. Technologies such as surgical robotics, artificial intelligence (AI) and 5G-enabled remote surgery are solving challenges in the delivery of surgical care and meeting emerging patient demand for more precise and advanced treatment methods.

Reimbursement and the affordability of digital health technologies, such as robotic surgery are key factors influencing uptake of the technology. To bring robotic surgery to more hospitals and patients, addressing cost-related challenges is crucial. The high costs of robotic surgery equipment remains a key deterrent for mid-sized and smaller hospitals in investing in the technology; while the high out-of-pocket costs of robotic surgery is a major barrier for many patients in Asia due to limited reimbursement for robot-assisted procedures.

In dynamic market segments such as infectious disease testing, demand for IVD testing can change quickly and gaining clarity on future demand is a big challenge for the client, an IVD company. 

Enable winning go-to-market strategies by tracking fastest-growing opportunities and competitors’ share of business to prioritise customer and test areas for growth and investment.

Our clients receive access to data, analysis and forecasting to guide their decision making. To learn more about our range of solutions, contact Clearstate by filling in the form so that we can answer your questions.

Digital technology is emerging as a long-term driver of healthcare industry development in South Korea. The post-pandemic Korean New Deal announced by the government will pour more than US$130bn into economic development by 2025. This will cover the Digital New Deal where healthcare digital-driven healthcare, such as the use of robotics in surgery is a key area of focus.